The presence of anti-citrullinated protein antibodies (ACPA) does not affect the clinical response to adalimumab in a group of RA patients with the tumor necrosis factor (TNF) α-308
Lilian Soto, Francisca Sabugo, Diego Catalan, Pamela Wurmann, Tomás Cermenatti, Héctor Gatica, Octavio Aravena, Lorena Salazar, Juan Carlos Aguillón, Miguel CuchacovichVolume:
30
Language:
english
Pages:
5
DOI:
10.1007/s10067-011-1679-4
Date:
March, 2011
File:
PDF, 112 KB
english, 2011